3/23/2023 6:45:34 PM
Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) FY23 Estimate To 0.02 From -0.69
3/23/2023 6:45:19 PM
Wedbush Is Increasing Magenta Therapeutics, Inc. (MGTA) Q4 23 Estimate To 0.01 From -0.05
3/23/2023 6:45:07 PM
Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q3 23 Estimate To 0.01 From -0.09
3/23/2023 6:44:53 PM
Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q2 23 Estimate To 0.01 From -0.17
3/23/2023 6:44:40 PM
Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q1 23 Estimate To 0.01 From -0.38
3/23/2023 6:43:58 PM
Wedbush Reiterates Magenta Therapeutics, Inc. (MGTA) At Neutral With $1 Price Target
5/16/2022 8:17:47 AM
Magenta Therapeutics Q1 Net Loss $23.0 Mln Vs. Net Loss Of $17.5 Mln Prior Year
3/8/2022 8:08:20 AM
Magenta Therapeutics Q4 Net Loss $19.3 Mln Vs. Net Loss $18.2 Mln Last Year
10/4/2021 8:05:27 AM
Magenta Therapeutics Appoints Jeffrey Humphrey As Chief Medical Officer
9/15/2021 8:23:02 AM
Magenta Therapeutics Announces IND Clearance For MGTA-117 Targeted Conditioning Clinical Trial
7/21/2021 8:07:10 AM
Magenta Therapeutics Gets Clinical Hold Letter From FDA Regarding IND On Acute Myeloid Leukemia And MDS
7/6/2021 8:04:31 AM
Magenta Therapeutics Appoints Caren Deardorf As Chief Commercial Officer
5/12/2021 10:08:40 AM
Magenta Therapeutics To Sell Around 9,600,000 Shares To Certain Institutional Investors In A Private Placement
4/19/2021 8:04:19 AM
Magenta Therapeutics Appoints David Nichols As Chief Technical Officer
5/10/2019 7:50:46 AM
Wedbush Is Increasing Magenta Therapeutics, Inc. (MGTA) FY19 Estimate To -1.97 From -2.49
5/10/2019 7:50:32 AM
Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q4 19 Estimate To -0.53 From -0.67
5/10/2019 7:50:09 AM
Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q3 19 Estimate To -0.48 From -0.60